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M A J O R A R T I C L E
Mannose-Binding Lectin in Severe Acute Respiratory
Syndrome Coronavirus Infection
W. K. Eddie Ip,1,a Kwok Hung Chan,2 Helen K. W. Law,1 Gloria H. W. Tso,1 Eric K. P. Kong,1 Wilfred H. S. Wong,1
Yuk Fai To,1 Raymond W. H. Yung,3 Eudora Y. Chow,4 Ka Leung Au,5 Eric Y. T. Chan,6 Wilina Lim,7
Jens C. Jensenius,8 Malcolm W. Turner,9 J. S. Malik Peiris,2 and Yu Lung Lau1
Departments of 1Paediatrics and Adolescent Medicine and 2Microbiology, The University of Hong Kong, 3Department of Pathology, Pamela
Nethersole Youde Hospital, and 4United Christian Hospital, 5Princess Margaret Hospital, 6Queen Mary Hospital, and 7Government Virus Unit,
Department of Health, Hong Kong, China; 8Department of Medical Microbiology and Immunology, University of Aarhus, Denmark; 9Immunobiology
Unit, Institute of Child Health, University College London, London, United Kingdom
Little is known about the innate immune response to severe acute respiratory syndrome (SARS) coronavirus
(CoV) infection. Mannose-binding lectin (MBL), a key molecule in innate immunity, functions as an ante-
antibody before the specific antibody response. Here, we describe a case-control study that included 569
patients with SARS and 1188 control subjects and used in vitro assays to investigate the role that MBL plays
in SARS-CoV infection. The distribution of MBL gene polymorphisms was significantly different between
patients with SARS and control subjects, with a higher frequency of haplotypes associated with low or deficient
serum levels of MBL in patients with SARS than in control subjects. Serum levels of MBL were also significantly
lower in patients with SARS than in control subjects. There was, however, no association between MBL genotypes,
which are associated with low or deficient serum levels of MBL, and mortality related to SARS. MBL could bind
SARS-CoV in a dose- and calcium-dependent and mannan-inhibitable fashion in vitro, suggesting that binding
is through the carbohydrate recognition domains of MBL. Furthermore, deposition of complement C4 on SARS-
CoV was enhanced by MBL. Inhibition of the infectivity of SARS-CoV by MBL in fetal rhesus kidney cells (FRhK-
4) was also observed. These results suggest that MBL contributes to the first-line host defense against SARS-CoV
and that MBL deficiency is a susceptibility factor for acquisition of SARS.
Severe acute respiratory syndrome (SARS), a newly
emerged infectious disease of humans, has affected 125
countries, with 8098 cases and 774 deaths reported to
the World Health Organization (WHO) during the first
half of 2003 [1]. The most affected locations were main-
land China, Hong Kong, Taiwan, Singapore, and To-
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ronto, Canada [2–5]. A novel virus, the SARS coro-
navirus (SARS-CoV), was identified as the etiological
agent [6–8] and was subsequently confirmed by ful-
fillment of Koch’s postulates [9]. The genome of SARS-
CoV is sufficiently different from all previously known
coronaviruses to warrant its designation as a new co-
ronavirus group [10, 11]. The surface spike (S) protein
is a major target of the host immune response to co-
ronaviruses and plays an important role in the attach-
ment and fusion of the virus to host cells. Postgenomic
characterization of SARS-CoV has revealed that the gly-
cosylation of this surface S protein is a high-mannose
structure [12], but knowledge of the pathogenesis of
and immune responses to SARS-CoV is still limited.
Mannose-binding lectin (MBL) is a key pattern-rec-
ognition molecule in innate immunity and functions
as an ante-antibody, a humoral factor that plays a crit-
ical role in the first-line host defense before the pro-
duction of antibodies [13]. MBL binds, through its mul-
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tiple carbohydrate recognition domains (CRDs), to repeating
arrays of carbohydrate structures on microbial surfaces [14],
thereby activating the complement system via MBL-associated
serine protease (MASP)–1 and –2 [15, 16] (also known as “the
lectin pathway”) or enhancing phagocytosis by acting as an op-
sonin [17–19]. Single-nucleotide polymorphisms (SNPs) in the
promoter and coding regions of the MBL gene (mbl2) have func-
tional effects on serum levels of MBL [20–22]. MBL deficiency
increases the generalized susceptibility of an individual to infec-
tious diseases [23, 24]. Increased susceptibility to infection by
specific pathogens—including HIV, Cryptosporidium parvum,
and Neisseria meningitidis—in MBL-deficient individuals has also
been established [25–27]. MBL has also been shown to opsonize
and inhibit the infectivity of influenza A virus [28].
In the present study, we examined the role that MBL plays in
SARS-CoV infection. Our findings demonstrate that MBL-de-
ficient individuals are more susceptible to SARS. Furthermore,
MBL, through its CRDs, could bind SARS-CoV, leading to in-
hibition of infectivity independent of complement, although ac-
tivation of complement via the lectin pathway was observed.
PATIENTS, MATERIALS, AND METHODS
Patients and samples. Approval for the patient study was
granted by the Clinical Research Ethics Committee of the In-
stitutional Review Board of The University of Hong Kong/
Hospital Authority Hong Kong West Cluster. We included in
the study 569 Hong Kong Chinese patients with SARS who
were admitted to 5 hospitals in Hong Kong between 10 March
and 26 April 2003. These 569 patients represented 59.0% of
the total 965 patients with SARS who were admitted to these
5 hospitals during the above period. The male to female ratio
was similar between the 569 study patients (249:320) and the
whole cohort (410:555), and the mean (SD) age of the study
patients (41.2 [17.2] years) was similar to that of the whole
cohort (40.7 [17.8] years). The patients fulfilled the modified
WHO definition of SARS [29]. Either SARS-CoV antibody se-
roconversion or detection of SARS-CoV RNA in respiratory
secretions by real-time quantitative polymerase chain reaction
(PCR) was documented for at least 95% of the patients. The
SARS-CoV antibody and RNA test results were obtained from
the Government Virus Unit, Department of Health, Hong Kong
Government, and the Department of Microbiology, The Uni-
versity of Hong Kong. The demographic features and outcomes
of the patients were obtained from the eSARS database, which
is maintained by the Hospital Authority SARS Collaborative
Study Group. EDTA whole blood and serum samples—which,
after investigations, were archived in the departments of pa-
thology of Pamela Nethersole Youde Hospital, Princess Mar-
garet Hospital, Queen Mary Hospital, and United Christian
Hospital—were obtained from the 569 patients with SARS for
genotyping and MBL assay.
A population of Hong Kong Chinese comprising 1188 indi-
viduals who had either been recruited from the local commu-
nity or were healthy Red Cross blood donors served as control
subjects. Their mean  SD age was years; 658 were19.4 11.6
males, and 530 were females.
DNA was extracted from 200 mL of whole blood by use of
the DNA Blood Mini Kit (Qiagen), in accordance with the man-
ufacturer’s instructions, and was stored at 20C until further
use. Separated serum was frozen at 70C until further use.
Purification of MBL. MBL was purified from ethanol-frac-
tionated human plasma paste (donated by C. Dash, Blood
Products Laboratory, Elstree, UK), as described elsewhere [19].
Briefly, MBL was prepared by 2-step mannan-agarose affinity
purification, followed by positive removal of trace immuno-
globulin impurities. MBL prepared in this manner is noncova-
lently associated with MASP [15]. In addition, plasma-derived
MBL prepared by the State Serum Institute (Copenhagen, Den-
mark; donated by C. Koch) was also used in some experiments
and gave identical results.
Cells and virus. The fetal rhesus kidney cell line (FRhK-4)
(American Type Culture Collection) was grown in MEM (Gibco-
BRL) containing 10% heat-inactivated fetal calf serum (FCS)
(Gibco-BRL), at 37C in 5% CO2. The SARS-CoV strain used
in the present study was HKU39849 [6]. The TCID50 of the virus
was determined in microtiter plates in accordance with the Reed-
Muench method. Briefly, 100 mL of serial 10-fold dilutions of
virus were tested in quadruplicate on confluent layers of FRhK-
4 cells grown on 96-well tissue-culture plates (Corning-Costar),
and any cytopathic effect (CPE) was recorded after 2–3 days.
MBL genotyping and haplotyping. The SNPs in the pro-
moter (221 X/Y) and exon 1 (codon 54 A/B) of the MBL
gene were genotyped by use of 2 separate cycling reactions of
the TaqMan allele-discrimination system (Applied Biosystems),
as described in our previous study [30]. The MBL mutant allele
B is in linkage disequilibrium with the promoter polymorphism
X/Y; therefore, B occurs only with Y [22]. To date, no exceptions
to this association have been reported, and, accordingly, the
data from the 2 separate TaqMan PCR reactions were combined
to give 3 haplotypes: YA, YB, and XA. Therefore, 6 genotypes
were identified in the present study: YA/YA, YA/XA, XA/XA,
YA/YB, XA/YB, and YB/YB. YB is 1 of 3 mutant haplotypes
commonly referred to as “O” [31, 32]. The other 2 known
mutant haplotypes carrying structural polymorphisms, C (co-
don 57) and D (codon 52), were not tested for in the present
study, since they are present at an extremely low frequency and
probably were absent in the Chinese population [20, 21]. The
frequencies of 2-locus haplotypes composed of the promoter
and a structural allele were also estimated by performing the
haplotype procedure of SAS/Genetic Software (version 8.2; SAS
Institute), as described elsewhere [33]; the expectation-maxi-
mization algorithm was used to generate maximum-likelihood
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Table 1. Frequencies of MBL genotypes and haplotypes in 569 patients with severe acute re-
spiratory syndrome (SARS) and 1188 control subjects.
Variable
Patients
with SARS
(n p 569)
Control
subjects
(n p 1188)
x2 test
Multiple logistic
regression analysis
P OR (95%CI) Pa OR (95% CI)
MBL genotype !.001 .016
YA/YA 211 (37.1) 530 (44.6) … … … …b
YA/XA 148 (26.0) 311 (26.2) … … … 1.17 (0.88– 1.56)
XA/XA 20 (3.5) 53 (4.5) … … … 0.94 (0.52– 1.73)
YA/YB 125 (22.0) 207 (17.4) … … … 1.53 (1.12– 2.10)
XA/YB 49 (8.6) 68 (5.7) … … … 1.81 (1.14– 2.88)
YB/YB 16 (2.8) 19 (1.6) … … … 2.21 (0.98– 4.97)
YB carrier 190 (33.4) 294 (24.7) !.001 1.52 (1.22–1.90) !.001 1.55 (1.21–1.99)
MBL haplotype !.001 .001
YA 695 (61.1) 1578 (66.4) … … … …b
XA 237 (20.8) 485 (20.4) … … … 1.10 (0.89– 1.35)
YB 206 (18.1) 313 (13.1) … … … 1.51 (1.21– 1.90)
NOTE. Data are no. (%), unless otherwise noted. CI, confidence interval; OR, odds ratio. P ! .05 was considered
to be significant.
a P values were determined after adjustment for sex and mean age in patients with SARS vs. those in control
subjects, by use of multiple logistic regression analysis.
b Reference group.
Figure 1. Serum levels of mannose-binding lectin (MBL), for MBL
genotypes with or without the mutant allele B, in patients with severe
acute respiratory syndrome (SARS), 19–23 days after the onset of disease.
The horizontal bars indicate the medians for each genotype subgroup.
Individuals with undetectable serum levels of MBL (!0.053 mg/mL) are
not shown.
estimates of haplotype frequencies, given that genetic-marker
genotypes are under the assumption of Hardy-Weinberg Equi-
librium (HWE).
MBL assay. Serum levels of MBL were determined by use
of an ELISA in which a mouse monoclonal anti–human MBL
antibody (HYB 131-01; Antibody Shop), either unlabeled or
labeled with biotin, was used as the primary or secondary an-
tibody, respectively, as described elsewhere [34]. Horseradish-
peroxidase (HRP)–conjugated streptavidin and substrate so-
lution containing tetramethylbenzidine (R&D) were used for
detection of bound secondary antibody, in accordance with the
manufacturer’s instructions.
Binding of MBL to SARS-CoV. Ninety-six-well flat-bottom
polystryrene plates (Corning-Costar) were coated with either
100 mL (per well) of 103, 104, or 105 TCID50 of SARS-CoV or
1% (wt/vol) bovine serum albumin (BSA) diluted in PBS. After
incubation overnight at 4C, wells were blocked for 1 h at room
temperature with 1% BSA in PBS containing 0.05% NaN3, were
washed with Hanks’ balanced salt solution (HBSS; Gibco-BRL)
containing 0.05% Tween 20 (HBSS/tw), and were incubated for
2 h with 100 mL (per well) of 0, 1, 5, or 10 mg/mL MBL diluted
in HBSS containing 20 mmol/L CaCl2 (HBSS/Ca
2+). In some
experiments, wells were incubated with 100 mL of MBL dilut-
ed in either HBSS containing 20 mmol/L EDTA or HBSS/Ca2+
containing 2 mg/mL mannan from Saccharomyces cerevisiae
(Sigma-Aldrich). The plates were washed with HBSS/tw and
were incubated for 1.5 h at room temperature with 0.2 mg/mL
biotinylated monoclonal anti-MBL antibody (HYB 131-01; An-
tibody Shop) diluted in HBSS/Ca2+ containing 0.2% BSA.
Bound antibody was detected by use of HRP-conjugated strep-
tavidin and tetramethylbenzidine substrate solution (R&D), in
accordance with the manufacturer’s instructions. The binding
of MBL to immobilized SARS-CoV was evaluated by use of
absolute absorbance values measured at 450 nm (A450).
1700 • JID 2005:191 (15 May) • Ip et al.
Figure 2. Binding of mannose-binding lectin (MBL) to severe acute respiratory syndrome (SARS) coronavirus (CoV)–infected FRhK-4 cells. Binding
of MBL to SARS-CoV–infected FRhK-4 cells was observed (A and B ). Convalescent serum samples from patients with SARS with confirmed SARS-
CoV antibody seroconversion were also tested, and binding of specific IgG to SARS-CoV–infected FRhK-4 cells was detected (C and D ). Both MBL
and anti–SARS-CoV antibody from serum samples from patients with SARS did not bind uninfected FRhK-4 cells (data not shown). Confocal imaging
showed that the binding by MBL mostly occurred on the surface of the infected cell (B) and that the binding by specific IgG from serum samples
from patients with SARS occurred on both the surface and in the cytoplasm of the infected cell (D). Original magnifications, 200 (A and C ) and
600 (B and D ).
Deposition of complement C4 by the MBL pathway of com-
plement activation. Ninety-six-well flat-bottom polystryrene
plates were coated with either 100 mL (per well) of 105 TCID50
of SARS-CoV or 1% BSA diluted in PBS. After incubation
overnight at 4C, wells were blocked for 1 h at room temper-
ature with 1% BSA diluted in PBS containing 0.05% NaN3,
were washed 3 times with PBS containing 0.05% Tween 20
(PBS/tw), and were incubated with 100 mL (per well) of 0.16,
0.31, 0.625, 1.25, 2.5, or 5 mg/mL MBL diluted in 20 mmol/L
Tris-HCl, 10 mmol/L CaCl2, 1 mol/L NaCl, 0.05% (vol/vol)
Triton X-100, and 0.1% BSA (pH 7.4). The wells that received
no MBL (buffer only) were used as negative controls. After
incubation overnight at 4C, the wells were washed as described
above and were incubated for 1.5 h at 37C with 100 mL (per
well) of 4 mg/mL purified human complement component C4
(Quidel) diluted in 4 mmol/L barbital, 145 mmol/L NaCl, 2
mmol/L CaCl2, 1 mmol/L MgCl2, and 1.5 mmol/L NaN3 (pH
7.5). The wells were washed 3 times with PBS/tw, followed by
incubation for 1.5 h at room temperature with mouse mono-
clonal anti-C4 antibody (4 mg/mL; Quidel) diluted in PBS/tw.
The wells were washed as described above and were incubated
for 1 h at room temperature with 100 mL (per well) of HRP–
anti-mouse IgG (Dako) diluted 1:1000 in PBS containing 0.2%
BSA. The wells were washed and developed with tetramethyl-
benzidine substrate solution (R&D), as described above. The
deposition of complement C4 on SARS-CoV by the MBL path-
way was evaluated at A450, according to the following formula:
relative percentage of C4 of negativedepositionp (A A450 450
controls A450 of negative controls .)/( ) 100
Inhibition of the infectivity of SARS-CoV by MBL. SARS-
CoV (100 TCID50) was treated for 1 h at 37C with 0, 0.6, 1.3,
2.5, 5, 10, or 20 mg/mL MBL diluted in 100 mL of MEM. Treated
virus was added to confluent layers of FRhK-4 cells grown in
96-well plates (Falcon; Becton Dickinson). After 1.5 h of ab-
sorption, the wells were washed twice with MEM and incubated
with fresh MEM containing 1% FCS. A real-time quantitative
PCR specific to the 1b gene region of SARS-CoV, with extrac-
tion of viral RNA from the culture supernatant after 24 h of
incubation (as described elsewhere [35, 36]), was used to de-
termine the infectivity of SARS-CoV in FRhK-4 cells. In some
experiments, the percentage of culture cells producing CPE was
determined by light microscopy after 48–60 h of incubation of
infected cells; by 48 h, 100% CPE was observed in the cells
infected with untreated SARS-CoV (100 TCID50).
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Figure 3. Binding of mannose-binding lectin (MBL) to severe acute respiratory syndrome (SARS) coronavirus (CoV). Binding of MBL to SARS-CoV
was determined by use of a microtiter capture assay. Wells of microtiter plates were coated with SARS-CoV, and MBL was incubated for 2 h in the
virus-coated wells. A, Amount of MBL. Incubation with increasing amounts of MBL resulted in increasing levels of detected MBL bound to immobilized
SARS-CoV (D). In contrast, MBL binding did not increase when the wells were coated with bovine serum albumin (). B, Amount of SARS-CoV. The
amount of MBL binding was also dependent on the amount of SARS-CoV used to coat the wells. C, Presence of Ca2+, EDTA, and/or mannan. To
determine the nature of binding of MBL to SARS-CoV, MBL was incubated in wells coated with SARS-CoV in the presence of either Ca2+ or EDTA.
The binding of MBL to SARS-CoV was reduced to background levels in the presence of EDTA, indicating that the interaction of MBL with SARS-CoV
was Ca2+ dependent. Preincubation of MBL with 2 mg/mL mannan in the presence of Ca2+ also substantially reduced binding of MBL to SARS-CoV.
These data provide evidence that MBL bound to immobilized SARS-CoV via its carbohydrate recognition domains. Results are presented as mean 
SE and are representative of 4 experiments.
Statistical analysis. Statistical analysis was performed by
use of SAS software (version 6.12; SAS Institute). Comparisons
of sex and MBL genotype distributions between patient and
control groups or between subgroups of patients were per-
formed by use of the x2 test. Age difference between the groups
was analyzed by use of an unpaired t test. Serum levels of MBL
in any 2 groups were compared by use of the Mann-Whitney
U test. Multiple logistic regression analysis was used to inves-
tigate the association between SARS and MBL genotypes, after
adjustment for differences in age and sex. Multiple linear re-
gression analysis was also used to investigate factors that may
determine serum levels of MBL: MBL genotype, age, sex, and
disease status. A significance level of was used for allP ! .05
analyses.
RESULTS
Association between genotypes associated with low serum lev-
els of MBL and SARS. DNA from 569 patients with SARS
(median [interquartile range {IQR}] age, 41.2 [29–51] years;
249 males and 320 females) and 1188 control subjects (median
[IQR] age, 19.4 [10.2–28] years; 658 males and 530 females)
was genotyped for MBL promoter (X/Y) and structural (A/B)
polymorphisms (table 1). Three MBL haplotypes—YA, XA, and
YB—were identified, where the mutant allele B is in linkage
disequilibrium with the promoter alleles X and Y [22]. The
distributions of the haplotypes in patients with SARS and in
control subjects were in HWE ( and , re-Pp .518 Pp .778
spectively), and their frequencies were closely matched with
that estimated by haplotype analysis (data no shown), in which
the estimated frequency of XB was as low as 0.00004 in both
SARS patients and control subjects, suggesting that the mutant
allele B is very unlikely to occur with the promoter allele X.
There was a significant difference between patients with SARS
and control subjects in terms of their MBL genotypes (P! .001)
(table 1). Genotypes associated with low serum levels of MBL,
with the mutant allele B, were significantly overrepresented in
the patients with SARS. MBL haplotype frequencies also dif-
fered between patients with SARS and control subjects, and
there was a significantly higher frequency of the haplotype as-
sociated with MBL deficiency, YB ( ). The overall car-P ! .001
riage rate of YB was 33.4% in patients with SARS and 24.7%
in control subjects ( ; odds ratio [OR], 1.52).P ! .001
We subsequently analyzed carriage of the mutant allele B
in patients with SARS who died ( ) and in those whonp 55
were discharged from the hospital after recovery ( ).np 514
Carriage of YB did not differ between patients with SARS who
recovered and those who died (34.1% [175/514] vs 29.1%
[16/55]; ).Pp .56
Serum levels of MBL in patients with SARS. Serum levels
of MBL in 353 patients with SARS, 19–23 days after the onset
of disease, were determined. We found that the median serum
level of MBL in these patients (0.733 [IQR, 0.263–1.796] mg/
mL) was significantly lower than that in 1167 control subjects
(1.369 [IQR, 0.572–2.598] mg/mL) ( ); 13 patientsPp .0004
with SARS and 63 control subjects had undetectable serum
levels of MBL (!0.053 mg/mL). Multiple linear regression analy-
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Figure 4. Mannose-binding lectin (MBL)–mediated deposition of com-
plement C4 on severe acute respiratory syndrome (SARS) coronavirus
(CoV). Different concentrations of MBL were incubated overnight at 4C
in microtiter plates coated with SARS-CoV. A consistent amount of C4
protein (4 mg/mL) was then incubated for 1.5 h at 37C in the wells.
Incubation with increasing amounts of MBL resulted in increasing de-
position of complement C4 on SARS-CoV (). In contrast, deposition of
complement C4 did not increase when wells were coated with bovine
serum albumin (). Results are presented as mean  SE and are rep-
resentative of 2 experiments.
Figure 5. Inhibition of severe acute respiratory syndrome (SARS) co-
ronavirus (CoV) infection. SARS-CoV pretreated with different concentrations
of mannose-binding lectin (MBL) was added to confluent layers of FRhK-4
cells. After 1.5 h of absorption, the cells were washed and incubated with
fresh medium. The infectivity of SARS-CoV was determined by real-time
quantitative polymerase chain reaction specific to the 1b gene region of
SARS-CoV, with extraction of viral RNA from the culture supernatant after
24 h of incubation. Increasing amounts of MBL resulted in decreasing the
infectivity of SARS-CoV. Results are representative of 4 experiments.
sis further revealed that MBL genotype and age were the sig-
nificant factors that determined serum levels of MBL. The dif-
ference in serum levels of MBL between patients with SARS
and control subjects was due to the significantly higher fre-
quencies of genotypes with the mutant allele B, which was
associated with low serum levels of MBL (figure 1), in the pa-
tients with SARS.
Binding of MBL to SARS-CoV and complement activation.
MBL was found to bind to the surface of SARS-CoV–infected
FRhK-4 cells as well as to immobilized SARS-CoV, by use of a
microtiter capture assay (figures 2 and 3). The binding of MBL
to SARS-CoV was calcium dependent and mannan inhibitable,
suggesting that MBL, through its CRDs, can bind SARS-CoV.
The binding was dose dependent for both MBL and SARS-CoV
(figure 3). In addition, MBL was found to enhance deposition
of complement C4 on immobilized SARS-CoV, suggesting that
MBL activates complement on the virus via the lectin pathway
(figure 4).
Inhibition of the infectivity of SARS-CoV by MBL. We
further investigated the possible translation of binding of MBL
to inhibition of the infectivity of SARS-CoV. SARS-CoV (100
TCID50) preincubated in serum-free medium containing MBL
at different concentrations (0.6–20 mg/mL) was added to con-
fluent layers of FRhK-4 cells. After 24 h of incubation, the
infectivity of SARS was determined by use of a real-time quan-
titative PCR specific to the 1b gene region of SARS-CoV, with
extraction of viral RNA from the culture supernatant. MBL was
found to have an inhibitory effect on SARS-CoV infection, in
a dose-dependent fashion (figure 5). Such inhibition was also
observed in separate experiments that determined CPE in cul-
ture cells after 48–60 h of incubation; 175% inhibition of CPE
was observed when SARS-CoV was pretreated with 5 or 10 mg/
mL MBL, whereas partial inhibition of CPE (25%–50%) was
observed when SARS-CoV was pretreated with 1.25 or 2.5 mg/
mL MBL. No inhibition of CPE (i.e., 100% cells producing
CPE) was found when SARS-CoV was pretreated with 0.6 mg/
mL MBL, a concentration similar to the median serum level
(0.52 mg/mL) in healthy individuals with group II MBL ge-
notypes (e.g., MBL B carriers).
DISCUSSION
In the present study, we have shown that individuals either
heterozygous or homozygous for YB had an OR of 1.52 for
acquisition of SARS, and the frequency of YB was significantly
higher in patients with SARS than in control subjects. Increas-
ing ORs (1.53, 1.81, and 2.21) were indeed observed in the
individuals with genotypes carrying 1 mutant haplotype (YB)
with a haplotype associated with high serum levels of MBL
(YA), 1 mutant haplotype (YB) with a haplotype associated
with low serum levels of MBL (XA), and 2 mutant haplotypes
(YB) (i.e., YA/YB, XA/YB, and YB/YB, respectively). Since YB
is associated with low serum levels of MBL, we further estab-
lished that patients with SARS had serum levels of MBL that
were significantly lower than those in control subjects. We con-
clude, therefore, that low serum level of MBL is a susceptibility
factor for acquisition of SARS; this conclusion further supports
the role of MBL as a first line of defense in respiratory infec-
tions, as has been documented in many other clinical settings
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[37–40]. For example, polymorphisms associated with low serum
levels of MBL have been associated with frequency of respiratory
tract infections in children [37], higher risk of invasive pneu-
mococcal disease [38], greater mortality and impaired lung func-
tion related to cystic fibrosis [39], and more-frequent hospital
admissions with respiratory tract infections related to chronic
obstructive pulmonary disease [40]. Nevertheless, in the present
study, XA (low-expression promoter) was not associated with
susceptibility to SARS, possibly because the serum level of MBL
in XA carriers was higher than that in YB carriers and was already
sufficient to avert infection with SARS.
We also examined whether YB was associated with a greater
risk of death in patients with SARS. The carriage of YB, how-
ever, did not differ between patients with SARS who died and
patients with SARS who recovered. This lack of difference is
likely due to the small number of the former who were tested;
risk factors may not be easily detected in these patients, in
particular in those with small effect size. It is also possible that,
once an infection is established, many other factors contribute
to the interaction between infectious agents and host defenses.
We attempted to investigate the role that MASP-2 plays in
SARS-CoV infection, because MBL complexes with MASP-2
efficiently activate complement [18, 19]. A structural poly-
morphism (allele A or G in exon 3 of the MASP-2 gene) that
was recently found in the region encoding either a normal or
a mutant form of the MASP-2 first domain CUB1 [41] was
also genotyped in patients with SARS and control subjects (data
no shown). However, we did not find the mutant allele G, which
suggests that this allele, which is present in the Danish pop-
ulation at a gene frequency of 5%, is extremely rare in the
Chinese population. Further experiments will be required to
establish whether MASP-2 contributes to the immune response
to SARS-CoV infection.
To elucidate the mechanisms underlying how MBL affects
SARS-CoV infection, we investigated and demonstrated bind-
ing of and inhibition of the infectivity of SARS-CoV by MBL.
MBL has been shown to function as an opsonin for other re-
spiratory viruses, such as influenza A virus, and to inhibit hem-
agglutination and the infectivity of several strains of influenza
A virus [28]. MBL inhibits hemagglutination and neutralizes
the infectivity of influenza A virus by binding to the N-linked
high-mannose carbohydrate side chain at the tip of the hem-
agglutinin S, thereby blocking the access of cell-surface recep-
tors to the receptor-binding site on hemagglutinin [42]. Sim-
ilarly, the S protein of SARS-CoV has 23 potential N-linked
glycosylation sites [10], and some of the sites are glycosylated
with high-mannose structures [12]. MBL selectively binds to
mannose, glucose, l-fucose, n-acetylmannosamine, and n-ace-
tylglucosamine, whereas galactose is not bound [43]. Since the
binding of MBL to SARS-CoV could be inhibited by mannan
and since this binding was Ca2+ dependent, it is likely that the
binding of MBL to SARS-CoV is through the interaction of
the CRDs of the MBL with the mannose side chains of the S
protein of SARS-CoV.
In vitro inhibition of the infectivity of SARS-CoV by MBL
was achieved at physiological levels. Since MBL may mediate
complement activation, as demonstrated by our assay for in
vitro deposition of complement C4, and modulate phagocytosis
of SARS-CoV by macrophages, resulting in other antiviral re-
sponses, the effect of MBL on SARS-CoV in vivo may be more
complex. Further experiments to delineate the relative roles
between MBL, complement, and macrophages, in control of
SARS-CoV infection, are required.
Accumulating evidence has shown that angiotensin-converting
enzyme 2 (ACE2), a metallopeptidase, is a functional receptor
for SARS-CoV that can bind to the S1 domain of the S protein
of SARS-CoV [44–46]. Anti-ACE2 antibody can block viral rep-
lication in African green monkey kidney cells (Vero E6) [44, 46].
Furthermore, a recombinant human antibody against the S1 do-
main of the S protein of SARS-CoV has been shown to neutralize
the virus on Vero E6 cells and inhibit formation of syncytia
between cells expressing the S protein and those expressing ACE2
[47]. MBL is a serum C-type lectin, and, here, we have dem-
onstrated that MBL binds SARS-CoV per se or infected cells and
inhibits the infectivity of the virus on rhesus monkey kidney
cells. These findings therefore support the possible role of MBL
in the host defense against SARS-CoV infection by targeting the
S protein of SARS-CoV before production of specific antibody.
Taken together, our findings suggest that MBL-deficient individ-
uals are more susceptible to SARS, and they provide insight into
the possible mechanisms of the innate immune response to
SARS-CoV infection. It will be important to assess the therapeutic
and prophylactic effect of replenishment of MBL in MBL knock-
out animal models of SARS.
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